Triple drug cocktail aims to wipe out CLL in first treatment
NCT ID NCT03580928
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests a combination of three drugs—acalabrutinib, venetoclax, and obinutuzumab—as an initial treatment for chronic lymphocytic leukemia (CLL). The goal is to see if this combo can make the cancer undetectable in the bone marrow after 15 cycles of therapy. The study enrolled 72 adults with untreated CLL, including some with a high-risk genetic form. Researchers are measuring how many patients achieve a complete response with no minimal residual disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib, venetoclax, and obinutuzumab (three drugs combined)
What this could lead to
If successful, this three-drug combination could offer a powerful initial treatment for CLL that may achieve deep remissions without the need for ongoing therapy.
What could go wrong
This is a mid-stage trial with only 72 participants, so results may not apply to all CLL patients. The combination also carries risks like infection and bleeding due to its effects on the immune system and blood cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Lifespan Cancer Institute
Providence, Rhode Island, 02903, United States
-
Stamford Hospital/Bennett Cancer Center
Stamford, Connecticut, 06904, United States